Clinical Trial Update: Abilify as an Adjunctive Treatment for Refractory Depression [Phase 4]

View source ↗

Summary

Phase 4 trial results for aripiprazole (Abilify) as an adjunctive treatment in adults with major depressive disorder have been posted; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: St. Luke's-Roosevelt Hospital Center | Conditions: Depressive Disorder, Major | Phase 4 | Status: COMPLETED | Results posted: 2015-02-20